Feb 28, 2020
CRISPR Edited Immune Cells Successful in First U.S. Clinical Trial
Posted by Kelvin Dafiaghor in categories: bioengineering, biotech/medical
Great news.
The successful delivery of CRISPR/Cas9 modified immune cells to cancer patients represents the first U.S. clinical trial to test the gene editing approach in humans.
Researchers from the Abramson Cancer Center of the University of Pennsylvania have published data suggesting that immune cells modified using the gene editing tool CRISPR/Cas9 are able to survive and function for months following delivery to cancer patients [1].
Continue reading “CRISPR Edited Immune Cells Successful in First U.S. Clinical Trial” »